Cancer & SURVIVEiT News
Category Filter:
New Genetic Signatures Could Advance Leukemia Precision Medicine
New Genetic Signatures Could Advance Leukemia Precision Medicine Using next-generation sequencing, researchers have discovered new genetic signatures that could facilitate precision medicine for children with leukemia. By Jessica Kent March…
FDA approves gemtuzumab ozogamicin for CD33-positive AML in pediatric patients
FDA approves gemtuzumab ozogamicin for CD33-positive AML in pediatric patients On June 16, 2020, the Food and Drug Administration extended the indication of gemtuzumab ozogamicin (MYLOTARG, Wyeth Pharmaceuticals LLC) for…
How A Leukemia Diagnosis Led To Donor Awareness & A Clothing Line
There were over 414,000 people living with leukemia in the United States in 2016, according to the National Cancer Institute. This particular type of cancer is found in blood and…
FDA approves longer-acting calaspargase pegol-mknl for ALL
On December 20, 2018, the Food and Drug Administration approved calaspargase pegol-mknl (ASPARLAS, Servier Pharmaceuticals LLC), an asparagine specific enzyme, as a component of a multi-agent chemotherapeutic regimen for acute…
FDA approves gilteritinib for relapsed or refractory AML with a FLT3 mutation
FDA approves gilteritinib for relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation On November 28, 2018, the Food and Drug Administration approved gilteritinib (XOSPATA, Astellas Pharma US…
FDA approves glasdegib for AML in adults age 75 or older or who have comorbidities
FDA approves glasdegib for AML in adults age 75 or older or who have comorbidities On November 21, 2018, the Food and Drug Administration approved glasdegib (DAURISMO, Pfizer Labs) in…
FDA approves Copiktra for leukemia, lymphoma subtypes
FDA approves Copiktra for leukemia, lymphoma subtypes September 25, 2018 The FDA approved duvelisib for the treatment of adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma…
FDA approves moxetumomab pasudotox-tdfk for hairy cell leukemia
FDA approves moxetumomab pasudotox-tdfk for hairy cell leukemia On Sept. 13, 2018, the Food and Drug Administration approved moxetumomab pasudotox-tdfk (LUMOXITI, AstraZeneca Pharmaceuticals LP), a CD22-directed cytotoxin indicated for adult…